Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis

被引：0
作者：
Georg Auzinger
E. Geoffrey Playford
Christopher N. Graham
Hediyyih N. Knox
David Weinstein
Michal Kantecki
Haran Schlamm
Claudie Charbonneau
机构：
[1] King’s College Hospital,
[2] Princess Alexandra Hospital,undefined
[3] RTI Health Solutions,undefined
[4] Research Triangle Park,undefined
[5] Pfizer International Operations,undefined
[6] Pfizer Inc,undefined
来源：
BMC Infectious Diseases | / 15卷
关键词：
Anidulafungin; Candidaemia; Echinocandin; Invasive Candidiasis; Cost-Effectiveness;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis
    Auzinger, Georg
    Playford, E. Geoffrey
    Graham, Christopher N.
    Knox, Hediyyih N.
    Weinstein, David
    Kantecki, Michal
    Schlamm, Haran
    Charbonneau, Claudie
    BMC INFECTIOUS DISEASES, 2015, 15
  • [2] Cost-effectiveness of anidulafungin in confirmed candidaemia and other invasive Candida infections in Spain
    Grau, S.
    Salavert, M.
    Carlos Pozo Laderas, J.
    Garcia Vargas, M.
    Barrueta, J. A.
    Mir, N.
    JOURNAL DE MYCOLOGIE MEDICALE, 2013, 23 (03): : 155 - 163
  • [3] Cost-effectiveness analysis and budgetary impact of anidulafungin treatment for patients with candidemia and other forms of invasive candidiasis in Brazil
    Vianna, Cid Manso de Mello
    Mosegui, Gabriela Bittencourt Gonzalez
    Rodrigues, Marcus Paulo da Silva
    REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO, 2023, 65
  • [4] Cost-effectiveness analysis of anidulafungin vs fluconazole for the treatment of invasive candidiasis (IC) in Turkey
    Neoh, Chin Fen
    Senol, Esin
    Kara, Ates
    Dinleyici, Ener Cagri
    Turner, Stuart J.
    Kong, David C. M.
    MYCOSES, 2017, 60 (11) : 714 - 722
  • [5] Resource Utilization and Cost of Treatment with Anidulafungin or Fluconazole for Candidaemia and Other Forms of Invasive CandidiasisFocus on Critically Ill Patients
    Annette C. Reboli
    Coleman Rotstein
    Daniel H. Kett
    Michael Maschio
    Shannon Cartier
    Richard Chambers
    Miriam Tarallo
    PharmacoEconomics, 2011, 29 : 705 - 717
  • [6] An open-label study of anidulafungin for the treatment of candidaemia/invasive candidiasis in Latin America
    Nucci, Marcio
    Colombo, Arnaldo L.
    Petti, Marco
    Magana, Martin
    Abreu, Paula
    Schlamm, Haran T.
    Sanchez, Sonia P.
    MYCOSES, 2014, 57 (01) : 12 - 18
  • [7] Anidulafungin for the treatment of invasive candidiasis
    Mayr, A.
    Aigner, M.
    Lass-Floerl, C.
    CLINICAL MICROBIOLOGY AND INFECTION, 2011, 17 : 1 - 12
  • [8] Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients
    Ruhnke, M.
    Paiva, J. A.
    Meersseman, W.
    Pachl, J.
    Grigoras, I.
    Sganga, G.
    Menichetti, F.
    Montravers, P.
    Auzinger, G.
    Dimopoulos, G.
    Borges Sa, M.
    Miller, P. J.
    Marcek, T.
    Kantecki, M.
    CLINICAL MICROBIOLOGY AND INFECTION, 2012, 18 (07) : 680 - 687
  • [9] Anidulafungin in the treatment of patients with invasive candidiasis
    Kett, Daniel H.
    Cubillos, G. Fernando
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2008, 32 : S99 - S102
  • [10] Appropriateness and cost-effectiveness in the treatment of invasive candidiasis in Internal Medicine Wards
    Tagliaferri, Enrico
    Menichetti, Francesco
    ITALIAN JOURNAL OF MEDICINE, 2014, 8 (04) : 221 - 224
12345